… Given that several lung cancer-derived mutants of … receptor autophosphorylation. However,
immunoblotting and immunohistochemistry show that cetuximab treatment of lung cancers …

Background To systematically investigate the relationship between CT morphological features
and the presence of epidermal growth factor receptor (EGFR) mutations in non-small cell …

… The Cancer Genome Project published what to our knowledge is the … mutations of HER2 in
lung cancers in 2004.19 Sequencing of HER2 in 120 lung tumors revealed somatic mutations …

… Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United …
States, lung cancer accounts for more deaths than breast, colon, prostate, and pancreas cancers …

… To determine whether lung tumors sensitive to gefitinib contained mutations … lung cancer
(NSCLC) who had been treated with gefitinib. Nine (45%) tumors had TK domain mutations. All …

… of ER and PR expression in lung cancers, but the … receptor expression and clinicopathologic
factors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer …

… ; or cancer genetic alteration, which may be dependent on the therapeutics methods and
treatment duration. As cancer stroma plays an essential role in lung … in a non‐cancer‐cell‐…

… Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified
in patients with advanced non–small cell lung cancer who achieve dramatic clinical and …

… receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) can predict the clinical
response to tyrosine kinase inhibitor (TKI) therapy. However, EGFR mutations … EGFR mutations …

… Twenty patients (24%) had EGFR mutations (deletions in or near E746-A750, n=16;
L858R, n=4). Epidermal growth factor receptor mutation status and patient clinicopathological …